Embryo's Genetic and Chromosomal Quality
Conditions
Brief summary
The aim of this study is to performed a randomized controlled trial to evaluate the rate of genetic and chromosomal abnormalities in embryos obtained from GnRH-agonist long and GnRH-antagonist ovarian stimulation protocols. Patients will be prospectively randomized in two groups: the first undergoing controlled ovarian stimulation in GnRH-agonist long protocol and the second following GnRH-antagonist ovarian stimulation regimen. The end-points of the study include the number of genetically and chromosomally abnormal embryos, the pregnancy, the implantation and the healthy baby birth rate. The patients included in PGS program were selected on the base of advanced maternal age, repeated pregnancy lost and implantation failure whereas the patients who were know to carry sex-linked or monogenic disorders were considered for PGD strategy. The uterine abnormalities, endometriosis and endocrinal diseases were considered to be the exclusion factors.
Interventions
DRUGghrh antagonist (cetrotide/orgalutran)
cetrotide/orgalutran 0.25 mg
DRUGgnrh agonist (suprefact)
suprefact 5.5 ml
Sponsors
European Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 46 Years
Healthy volunteers
No
Inclusion criteria
* patients carrier genetic disease * advanced maternal Age * repeated IVF failure * recurrent pregnancy loss
Exclusion criteria
* uterine abnormalities * endometriosis * endocrinal diseases
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The results of Preimplantation Genetic Diagnosis and Preimplantation Genetic Screening of embryos obtained from GnRH-agonist long and GnRH-antagonist ovarian stimulation protocol | one year | difference in embryos' genetic and chromosomal quality using two different ovarian stimulation protocol |
Countries
Italy
Outcome results
None listed